Date: 2011-02-11
Type of information: Development agreement
Compound: fosmidomycin, as a component of non-artemisinin based combination therapy (NACT), for acute Plasmodium falciparum malaria
Company: Jomaa Pharma (Germany) Medicines for Malaria Venture (MMV) (UK)
Therapeutic area: Infectious diseases - Parasitic diseases
Type agreement: development
Action mechanism: Fosmidomycin possesses antimalarial and antibacterial activity. This phosphonic antibiotic which inhibits 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr), the first committed step of the non-mevalonate pathway of isoprenoid biosynthesis.
Disease: malaria
Details: Jomaa Pharma and Medicines for Malaria Venture have signed a Memorandum of Understanding for the joint development of fosmidomycin, as a component of non-artemisinin based combination therapy (NACT), for acute Plasmodium falciparum malaria. The stimulus for this co-development project follows reports of the emergence of artemisinin resistance on the Thai-Cambodian border. A proof of concept study of fosmidomycin in combination with piperaquine is planned to take place in Thailand later this year. This will be followed by Phase II studies in children and toddlers in sub-Saharan Africa. The company is also collaborating with the European and Developing Countries Clinical Trials Partnership (EDCTP) to develop NACT products based on fosmidomycin under an existing grant.
Financial terms:
Latest news:
